Diabetes: Page 2
-
Dexcom connects G7 CGM directly to Apple Watch in US
Apple Watch and G7 users can now view real-time glucose readings on their wrist, regardless of whether they are carrying an iPhone.
By Nick Paul Taylor • Updated June 7, 2024 -
Abbott receives FDA OK for over-the-counter glucose monitor
After debuting its Lingo device in the U.K. last year, Abbott can now sell the sensor in the U.S.
By Elise Reuter • June 3, 2024 -
Medicare adviser sets recommendations for diabetes device evidence
A MEDCAC panel found time in range was an “extremely important” metric, but members were divided on whether quality of life measures should influence coverage.
By Elise Reuter • May 22, 2024 -
Dexcom details plans for over-the-counter CGM as insulin pump firms seek Type 2 coverage
Diabetes tech companies shared updates on new products, largely focused on Type 2 patients, in Q1 earnings calls.
By Elise Reuter • May 16, 2024 -
FDA targets health inequality by improving at-home devices
Michelle Tarver, an FDA official, said a new program is meant to advance health equity by considering people’s living conditions as part of medical device design.
By Elise Reuter • May 13, 2024 -
Tandem reports 224 injuries related to faulty insulin pump app
A problem with Tandem’s iPhone app could drain the battery of the connected insulin pump, causing it to power down sooner than expected.
By Nick Paul Taylor • May 9, 2024 -
Senseonics gets FDA clearance to pair CGM implant with insulin pumps
Analysts said the designation and planned one-year sensor could help Senseonics’ device appeal to more patients.
By Nick Paul Taylor • May 1, 2024 -
Boston Scientific, Dexcom and Edwards next as earnings season rolls on
J.P. Morgan analysts expect this week’s results to be “very good” following reports from J&J, Abbott and Intuitive Surgical.
By Nick Paul Taylor • April 23, 2024 -
Insulet names Ana Maria Chadwick CFO
Chadwick succeeds Wayde McMillan, who left last year to become CFO for 3M’s health spinoff.
By Nick Paul Taylor • March 21, 2024 -
Deka’s automated insulin delivery system, powered by patient-led app, gets FDA clearance
Sequel Med Tech will sell the new system, which integrates with Tidepool’s Loop insulin dosing algorithm.
By Nick Paul Taylor • March 20, 2024 -
Better Therapeutics lays off staff, considers winding down business
The digital therapeutics developer received authorization for a Type 2 diabetes treatment app last year but has struggled for money.
By Nick Paul Taylor • March 15, 2024 -
Dexcom’s over-the-counter nod sets stage for broader CGM use
The FDA’s decision allows people who don’t take insulin, including those who don’t have diabetes, to use the devices without a prescription.
By Elise Reuter • March 7, 2024 -
Roche to take on Abbott, Dexcom with its first CGM
The new sensor is designed to last for 14 days but requires finger-stick calibration.
By Nick Paul Taylor • March 7, 2024 -
Dexcom receives FDA clearance for first OTC glucose sensor
The diabetes tech firm is tailoring its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin.
By Nick Paul Taylor • March 6, 2024 -
Dexcom, Novo Nordisk call for FDA input on digital diabetes detection devices
The companies want clarity on what evidence would be needed for new technologies to detect undiagnosed Type 2 diabetes or prediabetes.
By Nick Paul Taylor • March 4, 2024 -
Insulet sizes up competition as Tandem, Medtronic plan new insulin patch-pumps
Insulet CEO Jim Hollingshead said the company is “very confident” in its competitive position as rivals develop their own patch pumps.
By Elise Reuter • Feb. 29, 2024 -
FDA warns against using smart wearables that claim to measure blood sugar
Unauthorized smartwatches and smart rings are “manufactured by dozens of companies and sold under multiple brand names,” according to the agency.
By Nick Paul Taylor • Feb. 23, 2024 -
Insulet wins CE mark for integration of insulin pump with Abbott CGM
The clearance positions Insulet to sell the integrated Type 1 diabetes product in Europe beginning in the first half of the year.
By Nick Paul Taylor • Feb. 8, 2024 -
FDA extends deadline for comments on role of digital health in diabetes detection
The agency is seeking answers on how digital health technologies could be used in the detection of prediabetes and Type 2 diabetes.
By Nick Paul Taylor • Jan. 31, 2024 -
Abbott says all four segments stronger than pre-pandemic
CEO Robert Ford said investing in its base business using COVID-19 testing revenues was “absolutely the right strategy.”
By Elise Reuter • Jan. 24, 2024 -
3 bellwether companies to watch as medtech earnings season begins
J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports.
By Nick Paul Taylor • Jan. 22, 2024 -
Abbott CEO talks diabetes market, device pricing at J.P. Morgan conference
CEO Robert Ford is “very confident” in Abbott’s ability to pass $10 billion in sales of its Libre continuous glucose monitor products by 2028.
By Elise Reuter • Jan. 10, 2024 -
Medtronic focused on delivering durable revenue and profit growth
“Our top priority is restoring our earnings power, full stop,” CEO Geoff Martha said Monday at the J.P. Morgan Healthcare Conference.
By Susan Kelly • Jan. 9, 2024 -
Dexcom plans to launch new CGM this summer for people who don’t take insulin
The company also shared earnings expectations for 2024 at the J.P. Morgan Healthcare Conference.
By Elise Reuter • Jan. 9, 2024 -
Abbott, Tandem launch new hybrid closed-loop insulin delivery system
Competitor Medtronic also received a CE mark for a new CGM sensor that can integrate with its 780G pump.
By Elise Reuter • Jan. 8, 2024